The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated massive gains, the end of its exclusive rights opened the avenue to generic alternatives, https://getidealist.com/story23580274/the-copyright-and-big-pharma-a-volatile-bet